Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Typherix
BIOLOGICAL
2 trials
Sponsors
Novartis
, Helsinki University Central Hospital
Conditions
Healthy
Typhoid Fever
Phase 1
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
Completed
NCT01123941
Novartis
Typhoid Fever
Start: 2010-05-31
End: 2010-11-30
Updated: 2014-01-17
Phase 4
Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines
NCT02121145
Helsinki University Central Hospital
Healthy
Start: 2013-10-31
End: 2019-12-31
Target: 100
Updated: 2014-04-23
Related Papers
Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.
2011-09-30
57 citations